2479 related articles for article (PubMed ID: 17950147)
1. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
Toblli JE; Lombraña A; Duarte P; Di Gennaro F
J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.
Okonko DO; Grzeslo A; Witkowski T; Mandal AK; Slater RM; Roughton M; Foldes G; Thum T; Majda J; Banasiak W; Missouris CG; Poole-Wilson PA; Anker SD; Ponikowski P
J Am Coll Cardiol; 2008 Jan; 51(2):103-12. PubMed ID: 18191732
[TBL] [Abstract][Full Text] [Related]
4. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes.
Comín-Colet J; Ruiz S; Cladellas M; Rizzo M; Torres A; Bruguera J
J Card Fail; 2009 Nov; 15(9):727-35. PubMed ID: 19879457
[TBL] [Abstract][Full Text] [Related]
5. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency.
Usmanov RI; Zueva EB; Silverberg DS; Shaked M
J Nephrol; 2008; 21(2):236-42. PubMed ID: 18446719
[TBL] [Abstract][Full Text] [Related]
6. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
[TBL] [Abstract][Full Text] [Related]
7. Combined endurance/resistance training reduces NT-proBNP levels in patients with chronic heart failure.
Conraads VM; Beckers P; Vaes J; Martin M; Van Hoof V; De Maeyer C; Possemiers N; Wuyts FL; Vrints CJ
Eur Heart J; 2004 Oct; 25(20):1797-805. PubMed ID: 15474694
[TBL] [Abstract][Full Text] [Related]
8. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.
Brito D; Matias JS; Sargento L; Cabral MJ; Madeira HC
Rev Port Cardiol; 2004 Dec; 23(12):1557-82. PubMed ID: 15732658
[TBL] [Abstract][Full Text] [Related]
9. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study.
Anwaruddin S; Lloyd-Jones DM; Baggish A; Chen A; Krauser D; Tung R; Chae C; Januzzi JL
J Am Coll Cardiol; 2006 Jan; 47(1):91-7. PubMed ID: 16386670
[TBL] [Abstract][Full Text] [Related]
10. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
[TBL] [Abstract][Full Text] [Related]
11. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.
Palazzuoli A; Silverberg DS; Iovine F; Calabrò A; Campagna MS; Gallotta M; Nuti R
Am Heart J; 2007 Oct; 154(4):645.e9-15. PubMed ID: 17892986
[TBL] [Abstract][Full Text] [Related]
12. No effect of group-based aerobic interval training on N-terminal pro- B-type natriuretic peptide levels in patients with chronic heart failure.
Nilsson BB; Westheim A; Risberg MA; Arnesen H; Seljeflot I
Scand Cardiovasc J; 2010 Aug; 44(4):223-9. PubMed ID: 20636229
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia.
Beck-da-Silva L; Rohde LE; Pereira-Barretto AC; de Albuquerque D; Bocchi E; Vilas-Boas F; Moura LZ; Montera MW; Rassi S; Clausell N
J Card Fail; 2007 Feb; 13(1):14-7. PubMed ID: 17338998
[TBL] [Abstract][Full Text] [Related]
14. Different characteristics of chronic heart failure (CHF) in elderly diabetics and non-diabetics.
Romeo R; Scalisi C; Tafuri L; Romeo A; Maugeri D; Sorace R
Arch Gerontol Geriatr; 2010; 50(1):101-4. PubMed ID: 19371958
[TBL] [Abstract][Full Text] [Related]
15. Changes in B-type natriuretic peptides after surgical ventricular restoration.
Sartipy U; Albåge A; Larsson PT; Insulander P; Lindblom D
Eur J Cardiothorac Surg; 2007 May; 31(5):922-8. PubMed ID: 17321144
[TBL] [Abstract][Full Text] [Related]
16. The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure.
Schou M; Gustafsson F; Corell P; Kistorp CN; Kjaer A; Hildebrandt PR
Am Heart J; 2007 Jul; 154(1):123-9. PubMed ID: 17584564
[TBL] [Abstract][Full Text] [Related]
17. Role of the plasma brain natriuretic peptide in differentiating patients with congestive heart failure from other diseases.
Sirithunyanont C; Leowattana W; Sukumalchantra Y; Chaisupamonkollarp S; Watanawaroon S; Chivatanaporn B; Bhuripanyo K; Mahanonda N
J Med Assoc Thai; 2003 May; 86 Suppl 1():S87-95. PubMed ID: 12866774
[TBL] [Abstract][Full Text] [Related]
18. [Values of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in evaluation of cardiac function in children with congenital heart disease].
Zhang SR; Zhang YH; Xu Q; Qiu HX; Chen Q
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jun; 11(6):429-32. PubMed ID: 19558803
[TBL] [Abstract][Full Text] [Related]
19. Aminoterminal B-type pro-natriuretic peptide as a marker of recovery after high-risk coronary artery bypass grafting in patients with ischemic heart disease and severe impaired left ventricular function.
Rothenburger M; Stypmann J; Bruch C; Wichter T; Hoppe M; Drees G; Berendes E; Huelsken G; Loeher A; Welp H; Röttger C; Schmid C; Scheld HH; Tjan TD
J Heart Lung Transplant; 2006 May; 25(5):596-602. PubMed ID: 16678040
[TBL] [Abstract][Full Text] [Related]
20. Ferric carboxymaltose in patients with heart failure and iron deficiency.
Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
